tirzepatide phase 3 trial for the Treatment of Obstructive Sleep Apnea and Obesity Read now: The SURPASS-EARLY trial
Description
In addition to competition among branded drugs, the arrival of generic versions and oral formulations which are typically cheaper to manufacture could further reduce costs
Why Some Patients Stay at Step 1 on Tirzepatide Tirzepatide is a dual GLP-1/GIP receptor agonist studied for chronic weight management at FDA-approved doses of 2.5 to 15 mg weekly
Common side effects include gastrointestinal symptoms (nausea, vomiting, diarrhoea), injection site reactions, and fatigue
It comes in single-dose pens, multi-dose KwikPens, or single-use vials that you inject with a needle and syringe
Switching from a compounded vial to an FDA-approved medication is a clinical decision rather than a straight swap, since doses do not always map one-to-one
Packaging of Wegovy Wegovy comes in a pen injector form
